GNI Group Ltd
TSE:2160

Watchlist Manager
GNI Group Ltd Logo
GNI Group Ltd
TSE:2160
Watchlist
Price: 3 380 JPY 5.13% Market Closed
Market Cap: 169.4B JPY
Have any thoughts about
GNI Group Ltd?
Write Note

Net Margin
GNI Group Ltd

31.7%
Current
14%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
31.7%
=
Net Income
7.2B
/
Revenue
22.7B

Net Margin Across Competitors

Country Company Market Cap Net
Margin
JP
GNI Group Ltd
TSE:2160
169.2B JPY
32%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
311.8B USD
9%
US
Amgen Inc
NASDAQ:AMGN
140.7B USD
13%
US
Gilead Sciences Inc
NASDAQ:GILD
115.7B USD
0%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.7B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
134.4B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36B EUR
-14%
Country JP
Market Cap 169.2B JPY
Net Margin
32%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 311.8B USD
Net Margin
9%
Country US
Market Cap 140.7B USD
Net Margin
13%
Country US
Market Cap 115.7B USD
Net Margin
0%
Country US
Market Cap 102.7B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 134.4B AUD
Net Margin
18%
Country US
Market Cap 78B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 36B EUR
Net Margin
-14%
No Stocks Found

GNI Group Ltd
Glance View

Market Cap
169.2B JPY
Industry
Biotechnology

GNI Group Ltd. engages in the development, research, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 629 full-time employees. The company went IPO on 2007-08-31. The firm is engaged in the development of therapeutic agents for diseases that have many sufferers in Asian countries such as Japan and China, as well as clinical trial and bio-verification test businesses. The company is engaged in research and development of therapeutic agents, including F647 for radiation pneumonia (RP) and idiopathic pulmonary fibrosis (IPF), F351 for liver fibrosis (cirrhosis) and F573 for acute hepatic insufficiency and acute chronic liver failure (ACLF).

Intrinsic Value
4 956.28 JPY
Undervaluation 32%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
31.7%
=
Net Income
7.2B
/
Revenue
22.7B
What is the Net Margin of GNI Group Ltd?

Based on GNI Group Ltd's most recent financial statements, the company has Net Margin of 31.7%.